ADAG - Adagene Inc

ADAG - Adagene Inc

https://www.adagene.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Is Adagene ( ADAG ) Stock Outpacing Its Medical Peers This Year?

Zacks Commentary • 6 days, 18 hours ago • score: 0.46

Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology ( CSCO ) Meeting in Jinan, China - Adagene ( NASDAQ:ADAG )

Benzinga • 1 week, 3 days ago • score: 0.25

SAN DIEGO and SUZHOU, China, Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Adagene Inc. ( "Adagene or the Company" ) ADAG, a company transforming the discovery and development of novel antibody-based therapies, today announced that ADG126 will be highlighted in two oral presentations at this year's CSCO ...

Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology ( CSCO ) Meeting in Jinan, China

GlobeNewswire • 1 week, 3 days ago • score: 0.25

SAN DIEGO and SUZHOU, China, Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Adagene Inc. ( "Adagene or the Company" ) ( Nasdaq: ADAG ) , a company transforming the discovery and development of novel antibody-based therapies, today announced that ADG126 will be highlighted in two oral presentations at this ...

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor - Adagene ( NASDAQ:ADAG )

Benzinga • 1 week, 5 days ago • score: 0.32

SAN DIEGO and SUZHOU, China, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Adagene Inc. ( "Adagene" ) ADAG, a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor.

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

GlobeNewswire • 1 week, 5 days ago • score: 0.31

SAN DIEGO and SUZHOU, China, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Adagene Inc. ( "Adagene" ) ( Nasdaq: ADAG ) , a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor.

Adagene to Participate in Two Investor Conferences in September - Adagene ( NASDAQ:ADAG )

Benzinga • 2 weeks, 6 days ago • score: 0.29

SAN DIEGO and SUZHOU, China, Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Adagene Inc. ( "Adagene or the Company" ) ADAG, a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chief Strategy Officer, Mickael Chane-Du, will participate in ...

Adagene to Participate in Two Investor Conferences in September

GlobeNewswire • 2 weeks, 6 days ago • score: 0.30

SAN DIEGO and SUZHOU, China, Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Adagene Inc. ( "Adagene or the Company" ) ( Nasdaq: ADAG ) , a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chief Strategy Officer, Mickael Chane-Du, will ...

Is Adagene ( ADAG ) Outperforming Other Medical Stocks This Year?

Zacks Commentary • 3 weeks, 4 days ago • score: 0.41

Here is how Adagene Inc. Sponsored ADR (ADAG) and CorMedix (CRMD) have performed compared to their sector so far this year.

This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Almonty Indus ( NASDAQ:ALM ) , Adagene ( NASDAQ:ADAG )

Benzinga • 1 month, 1 week ago • score: 0.31

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B ( End of Phase 1 ) Meeting with FDA

GlobeNewswire • 2 months ago • score: 0.23

- Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Adagene Inc., a clinical-stage biopharmaceutical company, is dedicated to the research, development, and production of monoclonal antibody drugs for cancer. The company is headquartered in Suzhou, China.

52W High

$3.58

52W Low

$1.33

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.75

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

1.12

EV/Revenue (<3 favorable)

549.06

P/S (TTM) (<3 favorable)

1091.47

P/B (<3 favorable)

2.97

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

4.70%

Institutions (25–75% balanced)

31.63%

Shares Outstanding

47,131,300

Float

15,915,600

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

103,200

Gross Profit (TTM)

103,200

EPS (TTM)

-0.64

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-322.84%

ROE (TTM) (>15% strong)

-0.63%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.87

Momentum

Bearish momentum

Value

0.0955

Previous

0.1097

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025